<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902021000100080</article-id>
<article-id pub-id-type="doi">10.29262/ram.v68i1.855</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Desensibilización a warfarina. Reporte de caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Warfarin desensitization. A case report]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fuentes-Abreu]]></surname>
<given-names><![CDATA[Fernando Steven]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ardila-Herrera]]></surname>
<given-names><![CDATA[Juan Camilo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Raigosa]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario San Vicente Fundación Servicio de Alergología Clínica ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2021</year>
</pub-date>
<volume>68</volume>
<numero>1</numero>
<fpage>80</fpage>
<lpage>83</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902021000100080&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902021000100080&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902021000100080&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes:  La warfarina es un anticoagulante oral ampliamente utilizado en la prevención y tratamiento de patologías tromboembólicas, a la cual se le atribuyen múltiples efectos adversos; no obstante, las descripciones de reacciones de hipersensibilidad son infrecuentes con este medicamento.  Caso clínico:  Paciente de 59 años, con antecedente de trombosis mesentérica, quien previamente recibió tratamiento prolongado con warfarina. Al suspender el medicamento, el paciente presentó recurrencia de trombosis a nivel hepatoesplénico y al reiniciar el cumarínico mostró reacción de hipersensibilidad. Se decidió continuar el tratamiento con warfarina por considerar que se trataba de la mejor opción terapéutica, motivo por el cual se realizó protocolo de desensibilización rápida.  Conclusión:  Las reacciones de hipersensibilidad con warfarina son infrecuentes; planteamos la opción de protocolo de desensibilización en pacientes que ameriten este medicamento cuando se considere mayor el beneficio clínico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background:  Warfarin is an oral anticoagulant which is widely used in the prevention and treatment of thromboembolic events, to which multiple adverse effects are attributed; nevertheless, descriptions of hypersensitivity reactions to this medication are rare.  Case report:  A 59-year-old patient with a history of mesenteric thrombosis, who had previously received long-term treatment with warfarin. Upon discontinuation of the medication, the patient experienced a recurrence of thrombosis at a hepatosplenic level, with a subsequent hypersensitivity reaction upon administration of the coumarin. It was decided that treatment with warfarin should be continued as it was considered the best therapeutic option, which is why a rapid desensitization protocol was carried out.  Conclusion:  Hypersensitivity reactions to warfarin are rare; we propose the option of a desensitization protocol for patients who require this medication as long as the clinical benefit is considered greater than the reaction.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Alergia]]></kwd>
<kwd lng="es"><![CDATA[Desensibilización]]></kwd>
<kwd lng="es"><![CDATA[Hipersensibilidad]]></kwd>
<kwd lng="es"><![CDATA[Warfarina]]></kwd>
<kwd lng="en"><![CDATA[Allergy]]></kwd>
<kwd lng="en"><![CDATA[Desensitization]]></kwd>
<kwd lng="en"><![CDATA[Hypersensitivity]]></kwd>
<kwd lng="en"><![CDATA[Warfarin]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mega]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacology of antithrombotic drugs an assessment of oral antiplatelet and anticoagulant treatments]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2015</year>
<volume>386</volume>
<numero>9990</numero>
<issue>9990</issue>
<page-range>281-91</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacons]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly]]></article-title>
<source><![CDATA[Cardiol Clin]]></source>
<year>2008</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>157-67</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Vogel]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[Dhond]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Marple]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Hauch]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation a cross-sectional survey]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2003</year>
<volume>25</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1750-64</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallerani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mandfredini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Moratelli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-haemorrhagic adverse reactions of oral anticoagulant therapy]]></article-title>
<source><![CDATA[Int J Cardiol]]></source>
<year>1995</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowe]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[McMeniman]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Warfarin-induced erythroderma]]></article-title>
<source><![CDATA[Australas J Dermatol]]></source>
<year>2015</year>
<volume>56</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skelley]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Thomason]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of direct oral anticoagulants in inherited thrombophilia]]></article-title>
<source><![CDATA[J Thromb Thrombolysis]]></source>
<year>2017</year>
<volume>43</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>24-30</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kwong]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Prescott]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tikoff]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dermatitis induced by warfarin]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>1978</year>
<volume>239</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1884-5</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheps]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gifford]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Urticaria after administration of warfarin sodium]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>1959</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>118-20</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gooderham]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse drug reactions and cutaneous manifestations associated with anticoagulation]]></article-title>
<source><![CDATA[J Cutan Med Surg]]></source>
<year>2017</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>540-50</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jameson]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Siri]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Induction of tolerance to warfarin after anaphylaxis with a desensitization protocol]]></article-title>
<source><![CDATA[Cardiology]]></source>
<year>2010</year>
<volume>115</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>174-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
